13F Holdings
中文EN

ELAB PMGC Holdings Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1840563 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-98.5%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin27.5%
Operating margin—
Net margin-275.7%
FCF margin-207.8%
EBITDA margin—

Returns

ROE-129.1%
ROA-18.0%
ROIC (approx.)—
Asset turnover0.07x

Leverage & solvency

Liabilities / assets15.8%
Debt / equity0.00x
Current ratio1.27x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-5.8%
Payout ratio—
Capex / revenue21.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31
Income statement
Revenue$590,084—$1.71M$766,277
Cost of revenue$404,770—$1.71M$318,968
Gross profit$185,314—$1.13M$447,309
R&D expense$147,010$104,654$7,410$228,747
SG&A expense$2.24M$1.09M$347,653$1.02M
Interest expense$257,630$735,197$19,525$2,629
Pretax income-$7.75M-$4.02M——
Income tax$30,972———
Net income-$7.75M-$6.25M-$4.30M-$1.80M
EPS (basic)——-0.40-0.19
EPS (diluted)——-0.40-0.19
Balance sheet
Cash & equivalents$5.40M$3.98M$3.33M$1.15M
Short-term investments$572,054———
Receivables$245,423$5,276$3,072$12,854
Inventory$95,098—$495,667$230,145
Current assets$6.87M$6.05M$4.92M$1.55M
PP&E, net$885,520$1,087$1,741$53,119
Goodwill$977,774———
Intangibles$2.89M$2.80M——
Total assets$12.87M$8.99M$5.19M$1.89M
Current liabilities$3.94M$1.80M$1.30M$588,272
Total liabilities$5.03M$2.33M$1.36M$760,873
Shareholders' equity$7.84M$6.66M$3.83M$1.13M
Shares outstanding8,0705,22612,3849.57M
Cash flow statement
Operating cash flow-$5.93M-$5.49M-$4.56M-$1.59M
Capital expenditure$442,255$9,160$11,191—
Free cash flow-$6.38M-$5.50M-$4.57M—
Investing cash flow-$2.77M-$610,564-$11,191-$32,027
Financing cash flow$10.12M$6.76M$6.74M$2.36M
Depreciation & amortization$96,145$546$11,649$6,512
Stock-based compensation-$19,160$97,167$487,738$171,869

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.